Bivalirudin started during emergency transport for primary PCI. - Wikidata - awgldk - TriplyDB

Bivalirudin started during emergency transport for primary PCI.

Bivalirudin started during emergency transport for primary PCI.

http://www.wikidata.org/entity/Q45829299

about

Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments Management of Percutaneous Coronary Intervention Complications.Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.HEAT-PPCI: A clear and welcome win for heparin Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMA Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors Influence of Access, Anticoagulant, and Bleeding Definition on Outcomes of Primary Percutaneous Coronary Intervention: Early Experience of an US Academic Center Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials.Temporal Trends in Bleeding among Acute Coronary Syndrome Patients: Is It Going Up or Down? Does It Matter?Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention.Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis.Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience.Practice of ST-segment elevation myocardial infarction care in the Netherlands during four snapshot weeks with the National Cardiovascular Database Registry for Acute Coronary Syndrome.Acute coronary syndromes in 2013: Optimizing revascularization strategies in patients with ACS.The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions.Reperfusion therapy for ST-segment elevation myocardial infarction: has ECG information been underutilized?Recent advances in antithrombotic treatment for acute coronary syndromes.Strategies to reduce bleeding risk in acute coronary syndromes and percutaneous coronary intervention: new and emerging pharmacotherapeutic considerations.The history of coronary reperfusion.Lessons from primary PCI practice for the next decade.Commentary on highlighted late breaking trials in interventional cardiology at ESC, VIVA, TCT, and AHA 2013.Novel antiplatelet agents in acute coronary syndrome.ST elevation myocardial infarction: recent advances and updates.Prasugrel hydrochloride for the treatment of acute coronary syndromes.Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis.One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials.Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?Editor's Choice-Chest pain relief in patients with acute myocardial infarction.Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

P2860

Q26740181-FBE65B15-C3E1-4547-AB70-711A65CA5C59 Q26765488-EF927A4C-C03E-4B76-B19E-914354F9221E Q26798653-05E5CF51-29C8-4B16-94BF-82947F028BC7 Q26801144-C65E1260-9D15-4FAD-96D3-EBBDCA831629 Q26862694-DEC24C73-FD9D-4456-9B35-8AAF2C9B430C Q30400083-2AB37AC4-4627-4FB7-8F44-36ACCD2F7C0F Q33435616-2B28607F-F7D8-4636-BB6B-1340E5F1A39F Q33923787-F3043F77-4A89-49E0-9084-E5E22CF93DBA Q33952693-C7D453E3-1BB4-4800-90C9-3F5EFC9DD305 Q34217697-CD247761-DB66-4F9D-897E-3318D2716F49 Q34487339-DFD0D2FA-16CD-474A-92CB-EAD0F09BBE3A Q35141545-B493CF4B-852F-4A24-9A72-77737BAB4B86 Q35641465-FED574CE-7004-4357-8532-2B501E562AC8 Q36090735-9AD4C96D-A2AD-4D04-A957-2B61C7C8A1C6 Q36251279-D00D4325-6B02-44E7-8358-61EE3266130A Q36362768-924C5817-B33F-486E-ABD8-6FE6C6C39F3F Q36558491-45FE42C6-1DEF-45C3-9EFA-680DA48D94C9 Q37212502-D036FF1D-B465-43AE-B524-13C697452D23 Q37240704-1E63F1D3-FAE2-4D9D-89B0-123A13810247 Q37510674-6F29ABA4-F837-4696-A630-8539C7E3FAFB Q37707154-AFEF1D58-2449-4DF0-9600-26742522C396 Q38176235-2D2BBF32-2DA8-4110-8BCC-E4D7720D62F8 Q38205318-6442AC41-4AEC-405E-88F2-5F4B1377F5FC Q38210583-F5B77A2B-FD4E-4FE8-BA53-E960E413EF39 Q38216600-7C435DB7-2871-4638-8862-F6AB059CFAE4 Q38217692-B4339A36-CCC7-4744-83BF-D574030DE348 Q38229561-4B145B19-B4A9-40B6-B8CB-B29AD4AE7258 Q38229992-0B359FCE-F2B9-4C7A-8DD3-33D5E24B3949 Q38239197-AF5B7CF1-6DFE-40BF-B6D9-0ED1396DD03D Q38257119-D83AF5EA-D056-47DC-849F-1BE5754AE752 Q38263602-0FD9AA74-1BED-412A-961C-C5961CBDA1FB Q38336838-398FAA1E-1B09-4082-978A-A2FA26B1D6D9 Q38337424-FC1C434D-A8B4-433F-B39D-C45420CCE42C Q38379744-A5067644-F455-4BFF-A13A-64CC4EABC090 Q38381704-4ADCD47C-A819-441F-B9E9-EFE6332F8269 Q38383037-C647CD8E-39E8-4E43-B5F5-1ED6821ECD83 Q38391491-1B18C8A4-5ACE-43F0-9ACA-4A73D977220E Q38423493-44374E5B-0FBE-4835-B673-D3940372A290 Q38437111-99BF8420-499A-4041-B8DE-DCE537A83E1B Q38547727-E355FDC7-C41F-4067-B9ED-B3C9028E59B2

P2860

Bivalirudin started during emergency transport for primary PCI.

http://www.wikidata.org/entity/Q45829299

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Bivalirudin started during emergency transport for primary PCI.

@en

Bivalirudin started during emergency transport for primary PCI.

@nl

type

label

Bivalirudin started during emergency transport for primary PCI.

@en

Bivalirudin started during emergency transport for primary PCI.

@nl

prefLabel

Bivalirudin started during emergency transport for primary PCI.

@en

Bivalirudin started during emergency transport for primary PCI.

@nl

P1433

Q45829299-2940CC95-DF46-4828-9A0F-CA5775839A86

P1476

Q45829299-497A6FEB-EF9D-45A8-9C33-CA8CDC39CC21

P2093

Q45829299-09FF7301-1EF0-4958-A031-59255290D9FE

Q45829299-0BEE892F-343B-4AA1-BA7F-1B4863772132

Q45829299-11E43F86-72F6-4606-BEA9-63D5265CF0C6

Q45829299-1D1EE0C6-4402-4669-9F52-E3D09D76E9BD

Q45829299-251F7806-3DDA-4C0B-B6C6-8EE05FA88DF8

Q45829299-282F39BB-D1B1-4ED1-8894-844D8B4E5F75

Q45829299-2B0CFF4C-B570-4ACD-8DA5-3AEE2B3B4646

Q45829299-2E856C53-97CA-42A6-BB06-472BC982EB97

Q45829299-2EADCF3A-DB12-49BB-B3D9-4324F8849D2E

Q45829299-3A9273A7-93D9-485F-9575-E971D4F89858

P304

Q45829299-BD42D561-56D8-48D3-B2B5-187C71062215

P31

Q45829299-25D20888-ACD7-481D-99E1-CF4C9DED805F

P356

Q45829299-0BEEF808-72DD-4D40-B038-67FBB61E9619

P407

Q45829299-77AEB6E8-AF5B-4F1E-8F38-AD071AF8FB34

P433

Q45829299-2D59B3C5-71D0-484C-8D7F-E345DBC65FCA

P478

Q45829299-3ED6BAC8-0330-46E4-95AF-39D91F5EEB2D

P50

Q45829299-372DF56F-3601-46AE-9676-3F255F319322

Q45829299-80512852-AC9F-4067-AC51-2D5AF4D04BEB

P577

Q45829299-D4C54FF2-FD4F-4415-80A0-D73F7D4F9A42

P5875

Q45829299-13478575-1B29-4F4D-A6DE-B56D371E0FF1

P698

Q45829299-8711AE1B-A07E-4689-BE71-97AD8E17A0E9

P356

P1433

The New England Journal of Medicine

P1476

Bivalirudin started during emergency transport for primary PCI.

@en

P2093

Arnoud van 't Hof

http://www.w3.org/2001/XMLSchema#string

Christian W Hamm

http://www.w3.org/2001/XMLSchema#string

Debra Bernstein

http://www.w3.org/2001/XMLSchema#string

Diana Schuette

http://www.w3.org/2001/XMLSchema#string

EUROMAX Investigators

http://www.w3.org/2001/XMLSchema#string

Efthymios N Deliargyris

http://www.w3.org/2001/XMLSchema#string

Frédéric Lapostolle

http://www.w3.org/2001/XMLSchema#string

Gerrit Jan Eggink

http://www.w3.org/2001/XMLSchema#string

Holger Nef

http://www.w3.org/2001/XMLSchema#string

Jayne Prats

http://www.w3.org/2001/XMLSchema#string

P304

2207-2217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1311096

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Gabriel Steg

Jacob Steinmetz

P577

2013-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261058624

http://www.w3.org/2001/XMLSchema#string

P698

24171490

http://www.w3.org/2001/XMLSchema#string